OGTT-modeled and IVGTT-modeled parameters of insulin sensitivity and β-cell function
| YT2DM (n=25) | Control (n=15) | p Value | |
|---|---|---|---|
| OGTT-modeled parameters | |||
| Insulin sensitivity | |||
| QUICKI | 0.21±0.006 | 0.27±0.010 | <0.001 |
| OGIS (mL/min/m2) | 281.8±16.54 | 421.3±16.46 | <0.001 |
| β-cell function | |||
| HOMA-%B | 110.9±26.88 | 230.9±42.10 | 0.016 |
| IGI (pmol/mmol) | 32.5±13.39 | 378.4±181.53 | 0.080 |
| IGIC peptide (pmol/mmol) | 97.4±27.85 | 1584.2±985.26 | 0.155 |
| BCOG−insulin (pmol/mmol)] | 34.1±11.25 | 244.3±41.57 | <0.001 |
| BCOG−C peptide (pmol/mmol)] | 2978±772.0 | 15 267 ±2542.2 | <0.001 |
| Shape indices | |||
| WHOSHglucose (×10−3) (min–2×mmol/L) | 3.2±0.50 | 2.0±0.20 | 0.079 |
| WHOSHinsulin (×10−2) (min–2×μU/mL) | 2.8±0.60 | 7.0±1.33 | 0.008 |
| WHOSHC peptide (×10−3) (min–2×ng/mL*) | 1.3±0.28 | 3.4±0.60 | 0.004 |
| DI | |||
| DI (mL/min/m2)×(min×pmol/L)] (×108) | 600.6±164.33 | 2239.6±228.58 | <0.001 |
| IVGTT-modeled parameters | |||
| Insulin sensitivity | |||
| CSI (×10–4) ((min–1)×(μU/mL)–1] | 1.7±0.24 | 4.0±0.81 | 0.015 |
| β-cell function | |||
| AIR (pmol/L) | 73.5±25.49 | 487.5±64.49 | <0.001 |
| BCIV−insulin (pmol/mmol)] | 19.8±5.93 | 51.5±8.06 | 0.003 |
| BCIV−C peptide(pmol/mmol)] | 2297.3±422.48 | 3556.2±495.28 | 0.065 |
| DI | |||
| DI [(mL/min/m2)×(min×pmol/L)] (×104) | 60.8±13.18 | 1939.7±617.60 | 0.009 |
AIR, acute insulin response; BC, β-cell function; CSI, calculated SI; DI, disposition index; HOMA-%B, homeostatic model assessment for BC; IGI, insulinogenic index; IVGTT, intravenous glucose tolerance test; OGIS, Oral Glucose Insulin Sensitivity Index; OGTT, oral glucose tolerance test; YT2DM, youth onset type 2 diabetes mellitus; QUICKI, Quantitative Insulin Sensitivity Check Index; WHOSH, Whole-Ogtt-Shape-index.